OraSure Technologies (OSUR) Expected to Announce Quarterly Earnings on Wednesday

Posted by Geri Gentry on Jul 29th, 2026

OraSure Technologies (NASDAQ:OSUR – Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $28.85 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

OraSure Technologies Stock Up 1.5%

Shares of NASDAQ:OSUR opened at $4.02 on Wednesday. OraSure Technologies has a 12 month low of $2.08 and a 12 month high of $4.58. The company’s fifty day simple moving average is $4.11 and its 200 day simple moving average is $3.35. The firm has a market cap of $276.78 million, a price-to-earnings ratio of -3.87 and a beta of 1.01.

Analyst Upgrades and Downgrades

OSUR has been the subject of a number of research reports. Wall Street Zen upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $3.00.

Check Out Our Latest Analysis on OraSure Technologies

Insider Buying and Selling at OraSure Technologies

In other OraSure Technologies news, Director Steven Kyle Boyd purchased 25,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was bought at an average cost of $2.99 per share, with a total value of $74,750.00. Following the purchase, the director directly owned 113,462 shares of the company’s stock, valued at $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OSUR. Millennium Management LLC grew its position in OraSure Technologies by 71.1% in the third quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock valued at $6,781,000 after purchasing an additional 878,151 shares in the last quarter. Geode Capital Management LLC increased its stake in OraSure Technologies by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock valued at $5,611,000 after buying an additional 112,851 shares during the last quarter. Cannell Capital LLC lifted its position in OraSure Technologies by 33.7% during the 2nd quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after buying an additional 470,536 shares in the last quarter. Kotler Kevin bought a new stake in OraSure Technologies during the 4th quarter worth about $4,359,000. Finally, Bridgeway Capital Management LLC boosted its stake in shares of OraSure Technologies by 9.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock worth $5,371,000 after buying an additional 154,985 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

(Get Free Report)

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.